唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效

目的评估唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效。方法74例前列腺癌骨转移患者按简单随机分组方法分为3组:唑来膦酸联合89Sr治疗组（A组）25例，年龄46~87岁，中位年龄66岁；单独给予唑来膦酸治疗组（B组）25例，年龄43~89岁，中位年龄65岁；单独给予89Sr治疗组（C组）24例，年龄47~85岁，中位年龄66岁。其中，B组和C组为对照组。随访6个月，观察患者骨骼疼痛缓解情况和骨转移病灶数目改善情况。结果3组患者的基线特征相似。治疗后，A组总的疼痛缓解率为88.0%，B组和C组分别为72.0%和79.2%，A组疼痛缓解情况与B组和C组相比差异有统计学意义（χ2=8.959，P < 0.05）。A组骨转移病灶好转率为88.0%，B组和C组分别为44.0%和75.0%，A组病灶好转情况分别与B组、C组相比，差异有统计学意义（χ2=9.096，P < 0.05）。结论唑来膦酸联合89Sr治疗前列腺癌骨转移较单独给药具有更好的缓解疼痛作用，89Sr治疗可有效减少骨转移病灶，提高患者的生活质量。

Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases

Objective To evaluate the clinical curative effect of zoledronic acid combined with 89Sr for the treatment of prostate cancer patients with bone metastases.Methods A total of 74 prostate cancer patients were randomly divided into three groups according to treatment,as follows:Group A (n =25;median age,66 years;age range,46-87 years),zoledronic acid with 89Sr;Group B (n =25;median age,65 years;age range,43-89 years),zoledronic acid;and Group C (n=24;median age,66 years;age range,47-85 years),89Sr.Groups B and C were the control groups.All patients were followed up for 6 months,during which the status of bone pain relief and improvement in the number of bone metastatic lesions were observed.Results The three groups showed similar baseline characteristics.Total pain relief efficiency in group A was 88.0％,while those of the control groups were 72.0％ (group B) and 79.2％(group C).Pain palliation of group A significantly differed from those of groups B and C (x2=8.959,P＜0.05).Regression of bone metastatic lesions in group A was 88.0％,while those of the control groups were 44.0％ (group B) and 75.0％ (group C).Significant difference was found between group A and the two control groups (x2=9.096,P＜0.05).Conclusion Combined therapy of zoledronic acid and 89Sr in prostate cancer patients with painful bone metastases was more effective in treating pain and improving the quality of life than separate administration of zoledronic acid or 89Sr.